[Infective morbidity of replacement therapy in congenital coagulation deficiencies and its effects on demand of coagulation factors]. / La morbilidad infecciosa del tratamiento sustitutivo en los déficit congénitos de coagulación y su repercusión en la demanda de los factores de coagulación.
Med Clin (Barc)
; 97(8): 287-91, 1991 Sep 14.
Article
em Es
| MEDLINE
| ID: mdl-1943304
BACKGROUND: Analysis of the infective morbidity and mortality secondary to replacement hemotherapy in the population with congenital coagulation deficiencies (CCD) and their consequences on the demand for coagulation factors. METHODS: The 46 patients with CCD diagnosed in the autonomous community (AC) of the Balearic Islands (32 with hemophilia A, 6 with hemophilia B, 4 with von Willebrand's disease 2 with factor VII, 1 with factor X, and 1 with factor XII deficiencies) were investigated for infective morbidity and use of blood products from 1982 to 1987. RESULTS: 97% of the patients had some hepatitis marker, 77% had antibodies against human immunodeficiency virus (HIV) and 17% fulfilled the criteria for the acquired immunodeficiency syndrome (AIDS). There were 7 deaths (15%). The morbidity and mortality increased with age and use of blood products. There was a 46% reduction in factor VIII use between 1982 and 1986, from a mean yearly consumption per hemophiliac patient of 33444 international units (IU) to 18080 IU. CONCLUSIONS: The study results show a high prevalence of hepatitis and HIV, an important reduction in the demand of manufactured coagulation factors and a 15% reduction in the population with CCD during the study years.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Transtornos da Coagulação Sanguínea
/
Substitutos Sanguíneos
/
Síndrome da Imunodeficiência Adquirida
/
Hepatite Viral Humana
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Child
/
Female
/
Humans
/
Male
Idioma:
Es
Ano de publicação:
1991
Tipo de documento:
Article